Denoci-Op Pfs Inj 60MG

Composition

Denosumab 60 mg/1 mL (pre-filled syringe) injection

Uses of Denoci-Op Pfs Inj 60MG

Treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture; bone loss associated with androgen deprivation therapy (prostate cancer) or aromatase inhibitor therapy (breast cancer); increases bone mineral density and reduces fracture risk.

• •Reduces risk of vertebral and hip fractures
• •Increases bone mineral density
• •Lowers bone resorption
• •Convenient once-every-6-month dosing
• •Helps prevent therapy-induced bone loss (ADT/AI related)

How it works

Denosumab is a monoclonal antibody against RANKL (receptor activator of nuclear factor kappa-B ligand). By inhibiting RANKL, it reduces formation, function and survival of osteoclasts, thereby decreasing bone resorption and increasing bone mass.

Directions for use

For subcutaneous use only. Usual adult dose: 60 mg (1 mL) once every 6 months, administered by a healthcare professional (thigh, abdomen, or upper arm). Ensure adequate calcium and vitamin D supplementation; use as advised by the doctor.

Side effects

Common side effects of Denoci-Op Pfs Inj 60MG may include:

• •Back pain
• •musculoskeletal pain
• •pain in extremity
• •